Chromium induced clinical improvement in symptomatic hypoglycemia.
The present study included 20 patients indicating clinical symptoms of hypoglycemia, of which 19 showed a minimal glucose level in the tolerance curve above 2.2 mmol/L (limit for glucose induced hypoglycemia). This clinical state is defined here as "symptomatic hypoglycemia." All individuals were studied for effects of a daily intake for three mo of a yeast chromium supplement (125 micrograms Cr/d). The patients were followed by means of their oral glucose tolerance curve (1 g glucose/kg body wt) and by an interrogation scheme prior to during and after chromium supplementation. During three mo of chromium supplementation, a decrease was found in the negative part of the glucose tolerance curve, i.e., the part of the curve being below the fasting level in eight patients (40%). However, one mo after treatment, 10 patients out of 13 (77%) showed decreased areas of the negative part of the glucose tolerance curve compared to the values during treatment, and 11 out of 15 (73%) showed decreases in the negative part of the curve when post-treatment data were compared to ante-treatment data. The subjective clinical effects were followed by means of a questionnaire. Subjectively, the effects of organo-chromium were especially pronounced on chilliness. Thus seven (47%) indicated improvement and two (15%) indicated that the chilliness disappeared. However, trembling, emotional instability, and disorientation symptoms improved as well.
Clausen
J
J
Institute for Life Sciences and Chemistry, Roskilde University, Denmark.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D002857:Chromium / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires
D001786:Blood Glucose; D002857:Chromium